Lead Discovery, Chemistry Optimization, and Biological Evaluation Studies of Novel Biamide Derivatives as CB<sub>2</sub> Receptor Inverse Agonists and Osteoclast Inhibitors
作者:Peng Yang、Kyaw-Zeyar Myint、Qin Tong、Rentian Feng、Haiping Cao、Abdulrahman A. Almehizia、Mohammed Hamed Alqarni、Lirong Wang、Patrick Bartlow、Yingdai Gao、Jürg Gertsch、Jumpei Teramachi、Noriyoshi Kurihara、Garson David Roodman、Tao Cheng、Xiang-Qun Xie
DOI:10.1021/jm301212u
日期:2012.11.26
N,N′-((4-(Dimethylamino)phenyl)methylene)bis(2-phenylacetamide) was discovered by using 3D pharmacophore database searches and was biologically confirmed as a new class of CB2 inverse agonists. Subsequently, 52 derivatives were designed and synthesized through lead chemistry optimization by modifying the rings A–C and the core structure in further SAR studies. Five compounds were developed and also
N , N '-((4-(二甲氨基)苯基)亚甲基)双(2-苯基乙酰胺)是通过使用3D药效团数据库搜索发现的,并被生物学证实为一类新的CB 2反向激动剂。随后,在进一步的 SAR 研究中,通过修饰环 A-C 和核心结构,通过先导化学优化设计和合成了 52 种衍生物。开发了五种化合物并证实它们是 CB 2反向激动剂,具有最高的 CB 2结合亲和力(CB 2 K i为 22–85 nM,EC 50为 4–28 nM)和最佳选择性(CB 1 /CB 2235 到 909 倍)。此外,破骨细胞生成生物测定表明 PAM 化合物对破骨细胞形成有很大的抑制作用。特别是,化合物26即使在0.1 μM的低浓度下也表现出72%的抑制活性。细胞毒性试验表明,PAM 化合物对破骨细胞生成的抑制作用不是由其细胞毒性引起的。因此,这些 PAM 衍生物可作为开发新型抗骨质疏松药物的潜在先导物。